Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Amit Bar-OrHeinz WiendlXavier MontalbanEnrique AlvarezMaria DavydovskayaSilvia R DelgadoEvgeniy P EvdoshenkoNatasa GiedraitieneKatrin Gross-PajuSulev HaldreCraig E HerrmanGuillermo IzquierdoGuntis KarelisFritz LeutmezerMiroslav MaresJose E Meca-LallanaDalia MickevicieneJacqueline NicholasDerrick S RobertsonDenis V SazonovKenneth SharlinBharathy SundaramNatalia TotolyanMarta VachovaMartin ValisMorten BaggerDieter A HäringInga Ludwig Roman WilliMartin ZalesakWendy SuMartin MerschhemkeEdward J Fox

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Ofatumumab 20 mg q4w self-administered subcutaneously via autoinjector is bioequivalent to PFS administration and provides rapid B-cell depletion.

Keyphrases

multiple sclerosis
loop mediated isothermal amplification
white matter
open label
randomized controlled trial
double blind
placebo controlled